Levodopa, dopamine agonists and MAO-B inhibitors were comparable in the prevalence of their use in year 1, but, by year 5, levodopa was the most common class of PD medication, with over 80% of patients prescribed this drug. The gene discussed is MAOB; the disease is Parkinson disease.